Skip to main content
. Author manuscript; available in PMC: 2015 Apr 10.
Published in final edited form as: Cancer. 2008 Oct 1;113(7 0):1933–1952. doi: 10.1002/cncr.23655

TABLE 3.

Azacitidine Versus Conventional Care in Patients with Myelodysplastic Syndrome (n=358)*

Response, %
Therapy No. Treated CR PR Overall Median Survival, mo
Azacitidine 179 18 12 29 24.4
Conventional care 179 8 4 12 15.5
 Best support 1 4 5 11.5
 Low-dose cytarabine 8 4 12 15.3
 Chemotherapy (3+7) 36 4 40 15.7

CR indicates complete response; PR, partial response; 3+7, intravenous daunorubicin daily X3 plus continuous-infusion cytarabine daily X7.

*

See Fenaux 2007.217